Journal Menu
► Journal MenuJournal Browser
► Journal BrowserSpecial Issue "Advances in Drug Targeting for Central Nervous System Disease"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 30 June 2023 | Viewed by 1804
Special Issue Editors
Interests: Alzheimer's disease; Parkinson's disease; antimicrobials; synthesis of peptides
Special Issues, Collections and Topics in MDPI journals
Interests: endoplasmic reticulum stress; inflammation; NSAIDs; antidepressants; antioxidants; pharmacology
Interests: neuroprotection; neurotoxicology; nanoparticles; nanomedicine; drug development; cell signaling
Special Issue Information
Dear Colleagues,
Central nervous system (CNS) diseases such as psychiatric and neurological are a major challenge for medicine and public health worldwide. Currently available drugs offer temporary relief from the symptoms of the neurodegenerative disorder, but they do not arrest or reverse the disease. Adverse effects and resistance to traditional therapies require looking for new options. CNS diseases are multifaceted disorders with diverse and not fully understood pathophysiological mechanisms, e.g., the development of inflammatory processes, oxidative and endoplasmic reticulum stress, disturbance of neuronal-glial communication. The pathological processes are associated with specific signaling pathways, and their elements can become strategic points for development of new drugs and for new applications of already approved.
This Special Issue of Pharmaceutics titled “Advances in Drug Targeting for Central Nervous System Diseases”, will gather discoveries of new drug targets, drug formation and targeted delivery with emphasis on strategies that may alter signaling pathways involved in pathological processes of CNS diseases to stop their progress or even prevent them. Research papers and Reviews on drugs already approved and new molecules are welcome.
We are looking forward for your contribution.
Dr. Ivana Cacciatore
Dr. Anna Wiktorowska-Owczarek
Dr. Sokołowska Paulina
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CNS diseases
- disturbance of neuronal-glial communication
- drug targeting
- drug formation
- targeted drug delivery
- endoplasmic reticulum stress
- neurodegeneration
- neuroinflammation
- neuroplasticity
- neuroprotection
- neurotransmitters
- neurotrophins
- oxidative stress
- signaling pathways
